Key points
- Dr Chris Bremer appointed as CEO effective 1 October 2026
- Over 20 years of pharmaceutical and biotech leadership experience
- Extensive experience in drug development, commercialization, and strategic partnerships
Full summary
Neurizon Therapeutics Limited, a late-stage biotechnology company focused on neurodegenerative diseases, announces the appointment of Dr Chris Bremer as Chief Executive Officer, effective October 1, 2026. Dr Bremer brings over 20 years of international pharmaceutical and biotechnology leadership experience, including senior roles at Grünenthal. His expertise spans drug development, portfolio strategy, commercialization, and business development. Dr Bremer's appointment coincides with Neurizon's advancement of NUZ-001 through the Phase 2/3 HEALEY ALS Platform Trial, with topline results expected in late Q2 2027. His role will focus on guiding the company through clinical execution, regulatory readiness, and strategic planning.
Guidance
Topline results for NUZ-001 expected in late Q2 2027
Outlook
Dr Bremer's appointment aims to strengthen leadership and prepare for potential strategic pathways following clinical trial results.